Advances in migraine treatment - a review
DOI:
https://doi.org/10.12775/QS.2024.21.54055Keywords
migraine, treatment advances, CGRP receptor antagonists, seserotonin receptor agonists, lasmiditan, zavegepant, rimegepantAbstract
Introduction
Migraine is a heavily debilitating disease that ranks second place in Global Burden Disease. It is estimated that around 1 billion of people suffer from it. It also has a significant negative impact on health-related quality of life (HRQoL) of patients and can affect their social, occupational, academic and familial life. Thus, it is crucial that all of the patients receive an effective treatment.
Objectives
This article aims to review the most recent advances in treatment of migraine.
Methods
A Literature review of articles published in Pubmed between 2000 and 2024 using the following words ‘migraine’, ‘treatment advances’, ‘CGRP receptor antagonists’, ‘serotonin receptor agonists’, ‘lasmiditan’, ‘zavegepant’, ‘rimegepant’.
Results
Literature search provides several concepts of advances in migraine treatment. Apart from behavioral treatment, new drugs targeting calcitonin gene related receptors (CGRP) and serotonin receptors agonists are emerging.
Conclusion
Migraine is a debilitating disease which significantly reduces health related quality of life in patients. New drugs targeting calcitonin gene related receptors (CGRP) and serotonin receptors agonists give a chance for more effective and tailored treatment.
References
Abu Bakar, Norazah, Surat Tanprawate, Giorgio Lambru, Mariam Torkamani, Marjan Jahanshahi, and Manjit Matharu. 2016. ‘Quality of Life in Primary Headache Disorders: A Review’. Cephalalgia: An International Journal of Headache 36 (1): 67–91. https://doi.org/10.1177/0333102415580099.
Aguilar-Shea, Antonio L., Javier A. Membrilla Md, and Javier Diaz-de-Teran. 2022. ‘Migraine Review for General Practice’. Atencion Primaria 54 (2): 102208. https://doi.org/10.1016/j.aprim.2021.102208.
Ailani, Jessica. 2021. ‘Acute Migraine Treatment’. Continuum (Minneapolis, Minn.) 27 (3): 597–612. https://doi.org/10.1212/CON.0000000000000956.
Ashina, Messoud, Zaza Katsarava, Thien Phu Do, Dawn C. Buse, Patricia Pozo-Rosich, Aynur Özge, Abouch V. Krymchantowski, et al. 2021. ‘Migraine: Epidemiology and Systems of Care’. Lancet (London, England) 397 (10283): 1485–95. https://doi.org/10.1016/S0140-6736(20)32160-7.
Bartsch, T., and Peter J. Goadsby. 2003. ‘The Trigeminocervical Complex and Migraine: Current Concepts and Synthesis’. Current Pain and Headache Reports 7 (5): 371–76. https://doi.org/10.1007/s11916-003-0036-y.
Becker, Werner J. 2015. ‘Acute Migraine Treatment’. Continuum (Minneapolis, Minn.) 21 (4 Headache): 953–72. https://doi.org/10.1212/CON.0000000000000192.
Bigal, Marcelo E., Michel Ferrari, Stephen D. Silberstein, Richard B. Lipton, and Peter J. Goadsby. 2009. ‘Migraine in the Triptan Era: Lessons from Epidemiology, Pathophysiology, and Clinical Science’. Headache 49 Suppl 1 (February):S21-33. https://doi.org/10.1111/j.1526-4610.2008.01336.x.
Bose, Pyari, Nazia Karsan, and Peter J. Goadsby. 2018. ‘The Migraine Postdrome’. Continuum (Minneapolis, Minn.) 24 (4, Headache): 1023–31. https://doi.org/10.1212/CON.0000000000000626.
Burch, Rebecca C., Dawn C. Buse, and Richard B. Lipton. 2019. ‘Migraine: Epidemiology, Burden, and Comorbidity’. Neurologic Clinics 37 (4): 631–49. https://doi.org/10.1016/j.ncl.2019.06.001.
Burstein, Rami, Rodrigo Noseda, and David Borsook. 2015. ‘Migraine: Multiple Processes, Complex Pathophysiology’. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 35 (17): 6619–29. https://doi.org/10.1523/JNEUROSCI.0373-15.2015.
Cernuda-Morollón, Eva, Davinia Larrosa, César Ramón, Juan Vega, Pablo Martínez-Camblor, and Julio Pascual. 2013. ‘Interictal Increase of CGRP Levels in Peripheral Blood as a Biomarker for Chronic Migraine’. Neurology 81 (14): 1191–96. https://doi.org/10.1212/WNL.0b013e3182a6cb72.
Croop, Robert, Jennifer Madonia, David A. Stock, Alexandra Thiry, Micaela Forshaw, Abigail Murphy, Vladimir Coric, and Richard B. Lipton. 2022. ‘Zavegepant Nasal Spray for the Acute Treatment of Migraine: A Phase 2/3 Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Trial’. Headache 62 (9): 1153–63. https://doi.org/10.1111/head.14389.
Diener, Hans-Christoph, David W. Dodick, Peter J. Goadsby, Richard B. Lipton, Jes Olesen, and Stephen D. Silberstein. 2012. ‘Chronic Migraine--Classification, Characteristics and Treatment’. Nature Reviews. Neurology 8 (3): 162–71. https://doi.org/10.1038/nrneurol.2012.13.
Dodick, David W. 2005. ‘Triptan Nonresponder Studies: Implications for Clinical Practice’. Headache 45 (2): 156–62. https://doi.org/10.1111/j.1526-4610.2005.05031.x.
———. 2018. ‘Migraine’. Lancet (London, England) 391 (10127): 1315–30. https://doi.org/10.1016/S0140-6736(18)30478-1.
GBD 2016 Headache Collaborators. 2018. ‘Global, Regional, and National Burden of Migraine and Tension-Type Headache, 1990-2016: A Systematic Analysis for the Global Burden of Disease Study 2016’. The Lancet. Neurology 17 (11): 954–76. https://doi.org/10.1016/S1474-4422(18)30322-3.
Goadsby, Peter J., Philip R. Holland, Margarida Martins-Oliveira, Jan Hoffmann, Christoph Schankin, and Simon Akerman. 2017. ‘Pathophysiology of Migraine: A Disorder of Sensory Processing’. Physiological Reviews 97 (2): 553–622. https://doi.org/10.1152/physrev.00034.2015.
Golden L. Peters, PharmD. 2019. ‘Migraine Overview and Summary of Current and Emerging Treatment Options’, Current, New, and Emerging Therapies for the Prevention and Management of Migraine, 25 (January). https://www.ajmc.com/view/migraine-overview-and-summary--of-current-and-emerging-treatment-options.
‘Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd Edition’. 2018a. Cephalalgia: An International Journal of Headache 38 (1): 1–211. https://doi.org/10.1177/0333102417738202.
‘———’. 2018b. Cephalalgia: An International Journal of Headache 38 (1): 1–211. https://doi.org/10.1177/0333102417738202.
Khan, Zainab Z., Usman Ahmed, Faizan Shahzad, Muaz Ali, Kashif Tousif, Usman Ahmed, Qazi Muhammad Safwan, et al. 2023. ‘Safety and Efficacy of Zavegepant in Treating Migraine: A Systematic Review’. Cureus 15 (7): e41991. https://doi.org/10.7759/cureus.41991.
Kissoon, Narayan R., and Fred Michael Cutrer. 2017. ‘Aura and Other Neurologic Dysfunction in or with Migraine’. Headache 57 (7): 1179–94. https://doi.org/10.1111/head.13101.
Kuca, Bernice, Stephen D. Silberstein, Linda Wietecha, Paul H. Berg, Gregory Dozier, Richard B. Lipton, and COL MIG-301 Study Group. 2018. ‘Lasmiditan Is an Effective Acute Treatment for Migraine: A Phase 3 Randomized Study’. Neurology 91 (24): e2222–32. https://doi.org/10.1212/WNL.0000000000006641.
Labastida-Ramírez, Alejandro, Eloísa Rubio-Beltrán, Kristian A. Haanes, Kayi Y. Chan, Ingrid M. Garrelds, Kirk W. Johnson, Alexander H. J. Danser, Carlos M. Villalón, and Antoinette MaassenVanDenBrink. 2020. ‘Lasmiditan Inhibits Calcitonin Gene-Related Peptide Release in the Rodent Trigeminovascular System’. Pain 161 (5): 1092–99. https://doi.org/10.1097/j.pain.0000000000001801.
Leonardi, Matilde, Timothy J. Steiner, Ann T. Scher, and Richard B. Lipton. 2005. ‘The Global Burden of Migraine: Measuring Disability in Headache Disorders with WHO’s Classification of Functioning, Disability and Health (ICF)’. The Journal of Headache and Pain 6 (6): 429–40. https://doi.org/10.1007/s10194-005-0252-4.
Lipton, R. B., M. E. Bigal, M. Diamond, F. Freitag, M. L. Reed, W. F. Stewart, and AMPP Advisory Group. 2007. ‘Migraine Prevalence, Disease Burden, and the Need for Preventive Therapy’. Neurology 68 (5): 343–49. https://doi.org/10.1212/01.wnl.0000252808.97649.21.
Lipton, Richard B., Robert Croop, David A. Stock, Jennifer Madonia, Micaela Forshaw, Meghan Lovegren, Linda Mosher, Vladimir Coric, and Peter J. Goadsby. 2023. ‘Safety, Tolerability, and Efficacy of Zavegepant 10 Mg Nasal Spray for the Acute Treatment of Migraine in the USA: A Phase 3, Double-Blind, Randomised, Placebo-Controlled Multicentre Trial’. The Lancet Neurology 22 (3): 209–17. https://doi.org/10.1016/S1474-4422(22)00517-8.
Lipton, Richard B., Robert Croop, Elyse G. Stock, David A. Stock, Beth A. Morris, Marianne Frost, Gene M. Dubowchik, Charles M. Conway, Vladimir Coric, and Peter J. Goadsby. 2019. ‘Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine’. The New England Journal of Medicine 381 (2): 142–49. https://doi.org/10.1056/NEJMoa1811090.
Loder, Elizabeth, and Paul Rizzoli. 2018. ‘Pharmacologic Prevention of Migraine: A Narrative Review of the State of the Art in 2018’. Headache 58 Suppl 3 (November):218–29. https://doi.org/10.1111/head.13375.
Maniyar, Farooq H., Till Sprenger, Teshamae Monteith, Christoph J. Schankin, and Peter J. Goadsby. 2015. ‘The Premonitory Phase of Migraine--What Can We Learn from It?’ Headache 55 (5): 609–20. https://doi.org/10.1111/head.12572.
Mathew, Paul G., and Brad C. Klein. 2019. ‘Getting to the Heart of the Matter: Migraine, Triptans, DHE, Ditans, CGRP Antibodies, First/Second-Generation Gepants, and Cardiovascular Risk’. Headache 59 (8): 1421–26. https://doi.org/10.1111/head.13601.
Nicholson, Robert A., Dawn C. Buse, Frank Andrasik, and Richard B. Lipton. 2011. ‘Nonpharmacologic Treatments for Migraine and Tension-Type Headache: How to Choose and When to Use’. Current Treatment Options in Neurology 13 (1): 28–40. https://doi.org/10.1007/s11940-010-0102-9.
Noseda, Rodrigo, and Rami Burstein. 2013. ‘Migraine Pathophysiology: Anatomy of the Trigeminovascular Pathway and Associated Neurological Symptoms, Cortical Spreading Depression, Sensitization, and Modulation of Pain’. Pain 154 Suppl 1 (December):S44-53. https://doi.org/10.1016/j.pain.2013.07.021.
Noseda, Rodrigo, Moshe Jakubowski, Vanessa Kainz, David Borsook, and Rami Burstein. 2011. ‘Cortical Projections of Functionally Identified Thalamic Trigeminovascular Neurons: Implications for Migraine Headache and Its Associated Symptoms’. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 31 (40): 14204–17. https://doi.org/10.1523/JNEUROSCI.3285-11.2011.
Ong, Jonathan Jia Yuan, and Milena De Felice. 2018. ‘Migraine Treatment: Current Acute Medications and Their Potential Mechanisms of Action’. Neurotherapeutics: The Journal of the American Society for Experimental NeuroTherapeutics 15 (2): 274–90. https://doi.org/10.1007/s13311-017-0592-1.
Parikh, S. 2021. ‘Lasmiditan for Acute Treatment of Migraine’. Drugs of Today (Barcelona, Spain: 1998) 57 (2): 89–100. https://doi.org/10.1358/dot.2021.57.2.3238326.
Penzien, Donald B., Frank Andrasik, Brian M. Freidenberg, Timothy T. Houle, Alvin E. Lake, Gay L. Lipchik, Kenneth A. Holroyd, et al. 2005. ‘Guidelines for Trials of Behavioral Treatments for Recurrent Headache, First Edition: American Headache Society Behavioral Clinical Trials Workgroup’. Headache 45 Suppl 2 (May):S110-132. https://doi.org/10.1111/j.1526-4610.2005.4502004.x.
Peres, Mario Fernando Prieto, Juliane P. P. Mercante, Patricia R. Tobo, Helder Kamei, and Marcelo Eduardo Bigal. 2017. ‘Anxiety and Depression Symptoms and Migraine: A Symptom-Based Approach Research’. The Journal of Headache and Pain 18 (1): 37. https://doi.org/10.1186/s10194-017-0742-1.
Riesco, Nuria, Eva Cernuda-Morollón, Pablo Martínez-Camblor, Sara Pérez-Pereda, and Julio Pascual. 2020. ‘Peripheral, Interictal Serum S100B Levels Are Not Increased in Chronic Migraine Patients’. Headache 60 (8): 1705–11. https://doi.org/10.1111/head.13919.
Rizzoli, Paul. 2014. ‘Preventive Pharmacotherapy in Migraine’. Headache 54 (2): 364–69. https://doi.org/10.1111/head.12273.
Scott, Lesley J. 2020. ‘Rimegepant: First Approval’. Drugs 80 (7): 741–46. https://doi.org/10.1007/s40265-020-01301-3.
Seng, Elizabeth K., and Kenneth A. Holroyd. 2014. ‘Behavioral Migraine Management Modifies Behavioral and Cognitive Coping in People with Migraine’. Headache 54 (9): 1470–83. https://doi.org/10.1111/head.12426.
Silberstein, S. D., S. Holland, F. Freitag, D. W. Dodick, C. Argoff, E. Ashman, and Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. 2012. ‘Evidence-Based Guideline Update: Pharmacologic Treatment for Episodic Migraine Prevention in Adults: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society’. Neurology 78 (17): 1337–45. https://doi.org/10.1212/WNL.0b013e3182535d20.
Silberstein, Stephen D., David W. Dodick, Marcelo E. Bigal, Paul P. Yeung, Peter J. Goadsby, Tricia Blankenbiller, Melissa Grozinski-Wolff, Ronghua Yang, Yuju Ma, and Ernesto Aycardi. 2017. ‘Fremanezumab for the Preventive Treatment of Chronic Migraine’. The New England Journal of Medicine 377 (22): 2113–22. https://doi.org/10.1056/NEJMoa1709038.
Steiner, T. J., L. J. Stovner, R. Jensen, D. Uluduz, Z. Katsarava, and Lifting The Burden: the Global Campaign against Headache. 2020. ‘Migraine Remains Second among the World’s Causes of Disability, and First among Young Women: Findings from GBD2019’. The Journal of Headache and Pain 21 (1): 137. https://doi.org/10.1186/s10194-020-01208-0.
Varkey, Emma, Asa Cider, Jane Carlsson, and Mattias Linde. 2011. ‘Exercise as Migraine Prophylaxis: A Randomized Study Using Relaxation and Topiramate as Controls’. Cephalalgia: An International Journal of Headache 31 (14): 1428–38. https://doi.org/10.1177/0333102411419681.
Zobdeh, Farzin, Aziza Ben Kraiem, Misty M. Attwood, Vladimir N. Chubarev, Vadim V. Tarasov, Helgi B. Schiöth, and Jessica Mwinyi. 2021. ‘Pharmacological Treatment of Migraine: Drug Classes, Mechanisms of Action, Clinical Trials and New Treatments’. British Journal of Pharmacology 178 (23): 4588–4607. https://doi.org/10.1111/bph.15657.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Katarzyna Słychan, Agata Frańczuk, Aleksandra Makłowicz, Angelika Szpulak, Ewelina Kopczyńska, Julia Głoskowska, Michalina Grzelka, Katarzyna Kuleta, Aleksandra Elżbieta Łęska, Paulina Kejna
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 128
Number of citations: 0
